Fortress Biotech Inc Pref Series A (FBIOP) earnings
In the quarter ended June 2026, Fortress Biotech Inc Pref Series A had revenue of $18M, up 18.9% on a year earlier, and diluted EPS of -0.08.
Quarterly results
The last 12 quarters from Fortress Biotech Inc Pref Series A's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | $18M | +18.9% | -0.08 | -117.8% | -56.1% | 2026-08-13 |
| Mar 31, 2026 | $16M | +21.2% | 2.82 | — | -48.6% | 2026-05-14 |
| Dec 31, 2025 | $16M | +27.3% | — | — | -29.8% | 2026-03-31 |
| Sep 30, 2025 | $17M | +16.4% | 0.11 | — | -40.0% | 2025-11-14 |
| Jun 30, 2025 | $15M | +1.0% | 0.45 | — | -243.0% | 2025-08-14 |
| Mar 31, 2025 | $13M | +0.8% | -0.48 | — | -169.9% | 2025-05-15 |
| Dec 31, 2024 | $13M | -17.3% | — | — | -188.9% | 2025-03-31 |
| Sep 30, 2024 | $15M | -4.3% | -0.76 | — | -151.0% | 2024-11-14 |
| Jun 30, 2024 | $15M | -12.4% | -0.73 | — | -187.1% | 2024-08-13 |
| Mar 31, 2024 | $13M | +7.1% | -1.04 | — | -280.6% | 2024-05-15 |
| Dec 31, 2023 | $15M | -4.2% | — | — | -128.6% | 2024-03-28 |
| Sep 30, 2023 | $15M | -4.8% | -0.94 | — | -90.0% | 2023-11-14 |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for FBIOP.
Open FBIOP in InvestinglyQuestions
How did Fortress Biotech Inc Pref Series A do last quarter?
In the quarter ended June 2026, Fortress Biotech Inc Pref Series A had revenue of $18M, up 18.9% on a year earlier, and diluted EPS of -0.08.
From Fortress Biotech Inc Pref Series A's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.